Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany.
- European Society of Gene and Cell Therapy (ESGCT) Congress
Title: Novel targeted LNP delivery achieved in vivo CAR-T cell generation resulting in therapeutically relevant B-cell depletion
Session Date and Time: Wednesday, October 28, 2026, 1:30 - 3:30 p.m. CET
Session Title: Poster Session 1
Presenter: Harry An, Director, Process Development, Editas Medicine
Final Abstract Number: P0361
Title: Development of a configurable, GMP-ready manufacturing platform for targeted LNP therapeutics
Session Date and Time: Wednesday, October 28, 2026, 1:30 - 3:30 p.m. CET
Session Title: Poster Session 1
Presenter: Harry An, Director, Process Development, Editas Medicine
Final Abstract Number: P0781
Abstracts can be accessed on the conference website as they become available, and presentations will also be posted to the “Posters & Presentations” section of the Company’s website during the conferences.
In addition, management will participate in the following upcoming investor conference in November:
- Guggenheim 3rd Annual Healthcare Innovation Conference
Format: Fireside Chat
Date and Time: November 10, 2026, 2:30 p.m. ET
Location: Boston, Massachusetts
To access the live webcast of Editas Medicine’s Fireside Chat, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the event.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Investor and Media Contacts:
ir@editasmed.com
media@editasmed.com
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
6 ETFs To Diversify Away From AI
Are TIPS ETFs the Best Way to Fight Inflation?
What’s Ahead for Stocks This Quarter—and Where to Invest
United States